search
Back to results

Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study. (Achalaglie)

Primary Purpose

Esophageal Achalasia

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Esophageal Achalasia focused on measuring Achalasia, peroral endoscopic myotomy, neuro-glio-epithelial unit

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female 18 years and above;
  • Woman of child-bearing age, if using active (oral contraceptive pill, intrauterine device, contraceptive implant) and/or mechanical (condom, diaphragm) contraceptive method;
  • Treatment-naive (no pneumatic dilation, botox injection, Heller's myotomy) patient with HRM-diagnosed achalasia in whom POEM is indicated;
  • Thorough oral and written information about the protocol has been provided and patient's consent to participate in the study has been obtained;
  • The patient is insured under the French social security system.

Exclusion Criteria:

  • Active anticoagulant treatment or coagulation disorder
  • Past history of achalasia treatment (pneumatic dilation, botox injection, Heller's myotomy)
  • Pregnancy or breastfeeding
  • Patient under trusteeship, guardianship, placed under judicial protection, and/or unable to provide consent

Sites / Locations

  • Nantes UHRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Esophageal biopsies during POEM

Arm Description

In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020. The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse.

Outcomes

Primary Outcome Measures

Feasibility of the assessment of the NGEU and esophageal muscle tissue in biopsies taken during a POEM for achalasia.
Percentage of patients in whom the molecular and transcriptomic analyses of the NGEU and esophageal muscle tissue are possible

Secondary Outcome Measures

Full Information

First Posted
September 27, 2019
Last Updated
December 31, 2021
Sponsor
Nantes University Hospital
Collaborators
Rennes University Hospital, University Hospital, Angers, LA ROCHE SUR YON HOSPITAL, Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT04112693
Brief Title
Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study.
Acronym
Achalaglie
Official Title
Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 21, 2019 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
November 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
Collaborators
Rennes University Hospital, University Hospital, Angers, LA ROCHE SUR YON HOSPITAL, Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Achalasia is a primary esophageal motility disorder characterized on high-resolution manometry (HRM) studies by 100% failed peristalsis and elevated integrated relaxation pressure of the lower esophageal sphincter. It is further divided into 3 sub-types according to the Chicago classification v3.01. The pathophysiology of achalasia is poorly understood; however, the NGEU is increasingly recognized as playing a key role in the development of this disorder. Similarly, the esophageal muscle tissue is probably involved, but its sampling remained challenging until the recent advent of the POEM procedure. Indeed, it is now possible, easy and safe to take biopsies of the muscle tissue during POEM. Therefore, POEM not only represents an innovative and effective treatment for achalasia, but also an opportunity to better understand its underlying pathophysiological mechanisms. Currently available treatments for achalasia (pneumatic dilation (PD), Heller's myotomy (HM), botox injections, POEM) are "palliative" procedures that do not restore normal contractile function of the esophagus, but a better understanding of the pathophysiological mechanisms underlying this disorder could potentially help developing curative, or even preventative treatments. To date, muscle tissue sampled during a POEM has only been characterized qualitatively (normal, atrophic, hypertrophic) with no assessment of the enteric nervous system. Moreover, there has been no studies of the mucosal or NGEU anomalies on biopsies taken during a minimally invasive procedure for achalasia such as a POEM. This study aims to evaluate the feasibility of the assessment of NGEU and esophageal muscle tissue in biopsies taken during a POEM for achalasia. It also aims to determine whether specific biomarkers within the NGEU and muscle tissue can predict a better therapeutic response to a POEM. The goal is to include 30 patients within 12 months. Given that approximately 100 new cases of achalasia are diagnosed each year at the included centers, and that about 50% of treatment-naive patients are offered and accept to undergo a POEM, recruitment should be completed relatively rapidly. All POEMs will be performed at the CHU de Nantes by a single endoscopist who has already performed more than 100 procedures. Other than the complications related to the POEM itself, the addition of 14 esophageal biopsies required for our study is a very low-risk intervention. Biopsy sampling extends the length of the procedure by only 4-5 minutes and has not been associated with an increased risk of complications in a previous study. Patients will be evaluated at five time points: preinclusion visit (up to four months before the POEM), inclusion visit (day of the POEM), post-POEM phone calls (3-6, 9-12, 22-26 months after POEM). During the preinclusion visit, relevant information regarding inclusion/exclusion criteria, consent, HRM and pH impedance results, past medical history, and pregnancy status (if applicable) will be gathered. At each time point, current medical history, Eckhardt score2 and pH impedance results (if available) will be documented. The patient will also answer the quality of life (SF36)3 and nutritional status questionnaires and will undergo blood sampling for albumin and prealbumin levels. Additionally, on the day of the POEM, there will be another blood sampling for complete blood count, PT, APTT, serum electrolytes and CRP level. Finally, at each post-POEM phone calls, the occurrence of adverse events will be reported. Our primary hypothesis is that the analysis of mucosal and muscle tissue biopsies taken safely during a POEM will allow better characterization of transcriptomic and molecular remodeling of the mucosa (especially the NGEU) and the muscularis propria in achalasia. We also hypothesize that these anomalies could eventually serve as treatment targets and as a way of better stratifying patients according to achalasia type and treatment (in our case, POEM) response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Achalasia
Keywords
Achalasia, peroral endoscopic myotomy, neuro-glio-epithelial unit

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Esophageal biopsies during POEM
Arm Type
Experimental
Arm Description
In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020. The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse.
Intervention Type
Procedure
Intervention Name(s)
Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)
Intervention Description
In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020. The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse.
Primary Outcome Measure Information:
Title
Feasibility of the assessment of the NGEU and esophageal muscle tissue in biopsies taken during a POEM for achalasia.
Description
Percentage of patients in whom the molecular and transcriptomic analyses of the NGEU and esophageal muscle tissue are possible
Time Frame
Day 0
Other Pre-specified Outcome Measures:
Title
Feasibility of the assessment of Full Field Optical Coherence Tomographie analysis of the mucosa and esophageal muscle
Description
percentage of patients for whom FFOCT analysis of the mucosa and esophageal muscle is possible.
Time Frame
Day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female 18 years and above; Woman of child-bearing age, if using active (oral contraceptive pill, intrauterine device, contraceptive implant) and/or mechanical (condom, diaphragm) contraceptive method; Treatment-naive (no pneumatic dilation, botox injection, Heller's myotomy) patient with HRM-diagnosed achalasia in whom POEM is indicated; Thorough oral and written information about the protocol has been provided and patient's consent to participate in the study has been obtained; The patient is insured under the French social security system. Exclusion Criteria: Active anticoagulant treatment or coagulation disorder Past history of achalasia treatment (pneumatic dilation, botox injection, Heller's myotomy) Pregnancy or breastfeeding Patient under trusteeship, guardianship, placed under judicial protection, and/or unable to provide consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Isabelle ARCHAMBAUD, MD
Phone
02 40 08 31 52
Email
Isabelle.ARCHAMBEAUD@chu-nantes.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabelle ARCHAMBEAUD, MD
Organizational Affiliation
Nantes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nantes UH
City
Nantes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle ARCHAMBEAUD, MD
Email
EIsabelle.ARCHAMBEAUD@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
Isabelle ARCHAMBEAUD, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
25469569
Citation
Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE; International High Resolution Manometry Working Group. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015 Feb;27(2):160-74. doi: 10.1111/nmo.12477. Epub 2014 Dec 3.
Results Reference
result
PubMed Identifier
1451966
Citation
Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992 Dec;103(6):1732-8. doi: 10.1016/0016-5085(92)91428-7.
Results Reference
result
PubMed Identifier
1593914
Citation
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
Results Reference
result

Learn more about this trial

Assessment of the Neuro-glio-epithelial Unit (NGEU) in Biopsies Taken During Peroral Endoscopic Myotomy (POEM) for Achalasia: a Feasibility and Safety Study.

We'll reach out to this number within 24 hrs